-
As part of the discussion of how budgets can influence subject enrollment and retention, Jeffrey Adelglass, MD, CEO, Research Across America, Dallas, TX, ran through his Top 10 list of budget busters David Letterman style.
-
Whether you're on the sponsor side or the clinical site side, you're probably acutely aware of two trends in clinical research: Contract negotiation and study start-up are big stumbling blocks in the advancement of research.
-
-
Needlesticks a problem some may have thought solved by needle safety devices remain a top concern among nurses.
-
Roche Laboratories, Inc. has updated their package insert for their protease inhibitor, saquinavir (Invirase) to include the following drug interaction information and include new warnings regarding coadministration of saquinavir/ritonavir and digoxin (used in the treatment of various cardiac conditions).
-
Episodic, unexplained false positive results with an oral fluid rapid HIV test, have resulted in changed protocols in some clinics and an ongoing investigation by the Centers for Disease Control and Prevention.
-
On June 26, 2008, the Food and Drug Administration (FDA) granted approval for a generic Zidovudine Oral Solution USP, 50 mg/5 mL formulation manufactured by Cipla Limited of Mumbai, India.
-
A new CCR5 receptor antagonist called vicriviroc may become a key weapon in the antiretroviral arsenal.
-
During 2001-2006, male-to-male sex remained the largest HIV transmission category in the United States and the only one associated with an increasing number of HIV/AIDS diagnoses, according to new data by the Center for Disease Control and Prevention reports.
-
At least this is what one HIV clinic discovered after starting an HIV medication adherence program that rewards patients who achieve 95 percent adherence to medication regimens and clinic appointments with a dinner out at an upscale restaurant.